What You Should Know:
- LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
- The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD's collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Medtronic to Separate Diabetes Business into New Standalone Company
What You Should Know:
- Medtronic today announced its strategic decision to separate its Diabetes business into a new, independent, publicly traded company ("New Diabetes Company").
- The move aims to create a more focused Medtronic, with a simplified portfolio concentrated on high-margin growth markets, while simultaneously establishing a scaled, independent leader in the diabetes sector.
- The separation is expected to be completed within 18 months through a series of
Read More
Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR
What You Should Know:
- Abbott, a provider of continuous glucose monitoring (CGM) biowearable technology, has announced a landmark agreement with Epic Systems, a major provider of electronic health records (EHR).
- The first-of-its-kind collaboration for Abbott will integrate patient glucose data from its leading FreeStyle Libre CGM systems directly into Epic's EHR platform across the United States.
FreeStyle Libre Integration with Epic Aura
The integration leverages
Read More
Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM
What You Should Know:
- Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
- The collaboration will integrate Sequel's twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics' Eversense® 365 CGM system.
This partnership marks a notable advancement in diabetes
Read More
Eli Lilly’s Oral GLP-1 Shows Positive Trial Results for Type 2 Diabetes
What You Should Know:
- Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.
- Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More
FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System
What You Should Know:
- Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.
- The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More
DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies
What You Should Know:
- New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers demonstrate significantly higher adherence and lower healthcare costs compared to those using pharmacy channels.
- The study, titled "Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A
Read More
Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management
What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements
What You Should Know:
- Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology.
- This update provides users with greater flexibility and control over their diabetes management. The expanded parameters and enhanced features of Control-IQ+ are designed to address a broader range of individual needs, making automated insulin delivery more accessible and effective.
Automated Insulin Delivery
Read More
Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus
What You Should Know:
- Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.
- The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is
Read More
